Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints

Raymond Y Huang; Patrick Y Wen

doi:10.1016/j.mric.2016.06.003

Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints

Magn Reson Imaging Clin N Am. 2016 Nov;24(4):705-718. doi: 10.1016/j.mric.2016.06.003. Epub 2016 Sep 14.

Authors

Raymond Y Huang¹, Patrick Y Wen²

Affiliations

¹ Division of Neuroradiology, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: ryhuang@partners.org.
² Division of Neuro-Oncology, Department of Neurology, Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.

PMID: 27742111
DOI: 10.1016/j.mric.2016.06.003

Abstract

The Response Assessment in Neuro-Oncology (RANO) Working Group is an international multidisciplinary group whose goal is to improve response criteria and define endpoints for neuro-oncology trials. The RANO criteria for high-grade gliomas attempt to address the issues of pseudoprogression, pseudoresponse, and nonenhancing tumor progression. Incorporation of advanced MR imaging may eventually help improve the ability of these criteria to define enhancing and nonenhancing disease better. The RANO group has also developed criteria for neurologic response and evaluation of patients receiving immunologic therapies. RANO criteria have been developed for brain metastases and are in progress for meningiomas, leptomeningeal disease, spinal tumors, and pediatric tumors.

Keywords: Brain metastases; Endpoints; Gliomas; RANO; Response assessment.

Publication types

Review

MeSH terms

Brain / diagnostic imaging
Brain Neoplasms / diagnostic imaging*
Glioma / diagnostic imaging*
Humans
Magnetic Resonance Imaging*
Neuroimaging / methods*
Tomography, X-Ray Computed*